Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Adenoma, Islet Cell 1

Interventions

Specimen Handling 122pembrolizumab 118Magnetic Resonance Spectroscopy 107Carboplatin 86Cyclophosphamide 75Biopsy 68Cisplatin 63Paclitaxel 58Bevacizumab 56Gemcitabine 49Nivolumab 47fludarabine 44Dexamethasone 39Rituximab 38Pemetrexed 38Fluorouracil 37atezolizumab 36Docetaxel 36Doxorubicin 34Radiotherapy 33Leucovorin 33venetoclax 31Oxaliplatin 30Capecitabine 30Temozolomide 28Prednisone 28Standard of Care 27Radiation 27Letrozole 27Cetuximab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × sargramostim × 30 days × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡